Returns Breakdown
| Return on Investment | (73.68) | |
| Return on Assets | (0.44) | |
| Return on Equity | (0.39) | |
| Return Capital | 32.17 | |
| Return on Sales | (5.34) |
What can we learn from Advaxis (OTC:ADXS) latest price fluctuation
 | By Vlad Skutelnik | Macroaxis Story |
Advaxis Accounts Payable Turnover is relatively stable at the moment as compared to the past year. Advaxis reported last year Accounts Payable Turnover of 0.33. As of 09/09/2022, Accrued Expenses Turnover is likely to grow to 0.09, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (16.6 M). The reasoning behind this post is to forecast a future value of Advaxis using technical analysis. What exactly are Advaxis retail investors should expect in October?
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Michael Smolkin
This firm has a beta of 0.6136. Let's try to break down what Advaxis's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Advaxis will likely underperform. The beta indicator helps investors understand whether Advaxis moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Advaxis deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Ayala Pharmaceuticals. Your research has to be compared to or analyzed against Ayala Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Ayala Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Ayala Pharmaceuticals.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Ayala Pharmaceuticals. Regardless of method or technology, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Predictive Modules for Ayala Pharmaceuticals
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Ayala Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Watch out for price decline
Please consider monitoring Ayala Pharmaceuticals on a daily basis if you are holding a position in it. Ayala Pharmaceuticals is trading at a penny-stock level, and the possibility of delisting is much higher compared to other otcs. However, just because the otc stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Ayala Pharmaceuticals stock to be traded above the $1 level to remain listed. If Ayala Pharmaceuticals otc stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Ayala Pharmaceuticals's Liquidity
Ayala Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Ayala Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Ayala Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Ayala Pharmaceuticals' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Ayala Pharmaceuticals' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Ayala Pharmaceuticals's total debt and its cash.
Details
Advaxis is displaying above-average volatility over the selected time horizon. Investors should scrutinize Advaxis independently to ensure intended market timing strategies are aligned with expectations about Advaxis volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Advaxis' otc stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Advaxis' otc stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Ayala Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.